Use and tolerability of imatinib mesylate (Gleevec) in patients with Philadelphia-positive chronic myeloid leukemia during the first 100 days following bone marrow or stem cell transplantation
Phase of Trial: Phase I
Latest Information Update: 31 Jul 2012
At a glance
- Drugs Imatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions
- 26 May 2009 Actual end date is October 2007 as reported by ClinicalTrials.gov.
- 09 Oct 2007 Status change from recruiting to completed
- 20 Jul 2006 New trial record.